Quick Answer
Coya Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $46.82 million for the year ending 2025.
- Coya Therapeutics, Inc. showed an increase of +22.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Coya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $16.32 million | Q2 2023: $13.10 million | Q3 2023: $10.89 million | Q1 2024: $35.99 million | Q2 2024: $36.58 million | Q3 2024: $31.06 million | Q1 2025: $35.53 million | Q2 2025: $29.76 million | Q3 2025: $28.13 million.
- Over the full 5 years of available data (2021 to 2025), Coya Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 978.8%.
- Historical annual values: Fiscal year 2025: $46.82 million | Fiscal year 2024: $38.34 million | Fiscal year 2023: $32.63 million | Fiscal year 2022: $5.93 million | Fiscal year 2021: $4.34 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: